Kimberly-Clark (KMB) Q2 2026 (Q&A) earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 (Q&A) earnings summary
4 Aug, 2026Executive summary
Achieved net sales of $4.2 billion for Q2 2026, up 0.6% year-over-year, with organic sales flat due to China social media disruption impacting diaper sales.
Adjusted operating profit for Q2 rose 6.2% to $757 million, and adjusted EPS from continuing operations increased 10.4% to $1.80, driven by productivity gains and one-time tariff refunds.
Transformation initiatives advanced, including the Arbex joint venture with Suzano, a new sustainable materials pilot plant, and the pending Kenvue acquisition.
Q2 results were negatively impacted by false social media allegations affecting diaper sales in China, with independent tests confirming product safety.
The IFP segment was divested, with the transaction closing July 1, 2026, and results reported as discontinued operations.
Financial highlights
Q2 2026 net income attributable to shareholders was $345 million, down 32% year-over-year, mainly due to discontinued operations and higher tax expense.
Q2 gross margin was 38.3%; adjusted gross margin was 38.8%, up 190 bps year-over-year.
Q2 operating profit was $633 million; adjusted operating profit was $757 million, up 6.2% year-over-year.
Q2 diluted EPS from continuing operations was $1.22; adjusted EPS was $1.80, up 10.4% year-over-year.
Cash provided by operations for the first half was $1.7 billion, up from $1.1 billion last year.
Outlook and guidance
2026 organic sales growth expected to be about 100 bps below weighted average category growth due to China disruption and business exits.
Adjusted operating profit expected to grow mid-single digits, and adjusted EPS from continuing operations to grow high single digits on a constant-currency basis.
Adjusted free cash flow for 2026 expected to be ~$2 billion, with capital expenditures accelerating to ~$1.3 billion.
The Kenvue acquisition is expected to close in H2 2026, subject to regulatory approvals.
Continued near-term headwinds in China and incremental input costs of ~$150 million from Middle East conflict.
Latest events from Kimberly-Clark
- Adjusted EPS up 10.4% in Q2 2026, but China disruption tempers full-year outlook.KMB
Q2 2026 Prepared Remarks4 Aug 2026 - A $48.7B merger forms a global health leader, targeting $2.1B in synergies by 2029.KMB
M&A Announcement15 Jul 2026 - Q3 2024 delivered higher adjusted EPS and profit, reaffirming a strong 2024 outlook.KMB
Q3 20249 Jul 2026 - Premiumization, innovation, and efficiency drive double-digit shareholder returns and growth.KMB
Deutsche Bank dbAccess 2024 Global Consumer Conference8 Jul 2026 - 2025 targets volume-led growth, margin gains, and SG&A savings amid FX and divestiture headwinds.KMB
Q4 20248 Jul 2026 - Acquisition targets $1.9B in synergies, leveraging complementary strengths for growth.KMB
Morgan Stanley Global Consumer & Retail Conference 20258 Jul 2026 - Kenvue integration and innovation drive growth, productivity, and strong shareholder returns.KMB
23rd annual dbAccess Global Consumer Conference4 Jun 2026 - Strong growth, strategic acquisitions, and board elections defined the meeting's outcomes.KMB
AGM 202614 May 2026 - Transforming through innovation and acquisitions to build a global health and wellness leader.KMB
Barclays 18th Annual Americas Select Conference11 May 2026